FIELD: biochemistry.
SUBSTANCE: present invention relates to an antibody against human annexin (Anx-A1) having following hypervariable regions (CDR): VLCDR1 represents KASENWTYVS, VLCDR2 represents GASNRYT, VLCDR3 represents GQGYSYPYT, VHCDR1 represents GYTFTNYWIG, VHCDR2 represents DIYPGGDYTNYNEKFKG and VHCDR3 represents WGLGYYFDY. Present invention also discloses a hybridoma cell, deposited in European Collection of Cell Cultures (ECACC) under number 10060301, which produces said antibody. Antibody according to present invention is used as an active ingredient in composition for inhibiting activation of T-cells, as well as for preparing a drug for treating diseases caused by aberrant activation of T-cells, such as rheumatoid arthritis or multiple sclerosis.
EFFECT: present invention provides a novel monoclonal antibody specifically inhibiting activation of T-cells without any adverse cytotoxic effects.
18 cl, 17 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT | 2009 |
|
RU2554801C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| ANTIBODIES RECOGNISING CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS, AND METHODS OF USING SUCH | 2007 |
|
RU2461572C2 |
| METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587620C2 |
| ANTIBODIES RECOGNIZING CARBOHYDRATE-CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS OF APPLICATION | 2012 |
|
RU2616868C2 |
| METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587624C2 |
| BISPECIFIC BINDING AGENTS WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2535992C2 |
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
